BridgeBio Pharma Announces Progress in its KRAS Portfolio, New Gene Therapy Programs, and Updates on Advancements Across its R&D Pipeline Targeting Genetic Diseases and Cancers

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, is announcing...

Related Keywords

United States ,American ,Charles Homcy ,Bridgebio Bio ,Bridgebio Cardiorenal ,Katherine Yau ,Eli Wallace ,Mary Scott Roberts ,Richard Scheller ,Neil Kumar ,Jonathan Fox ,Suma Sinha ,Eric David ,Linkedin ,Twitter ,Drug Administration ,Nasdaq ,Exchange Commission ,Bridgebio Pharma Inc ,European Union ,Securities Exchange ,Bio Pharma Inc ,Mineral Research ,Stanford University ,American Society Of Bone ,Bridgebio Pharma ,Bridgebio Gene Therapy ,American Society ,Grace Rauh ,Cameron Turtle ,Bridgebio Oncology ,Bio Pharma ,Securities Act ,Securities Exchange Act ,Exchange Act ,Gene Therapy ,Risk Factors ,Bio Media Contact ,Bio Investor Contact ,Bridgebio ,